Aclaris Therapeutics Inc (ACRS)

$1.33

+0.01

(+0.76%)

Market is closed - opens 7 PM, 23 Jul 2024

Performance

  • $1.32
    $1.40
    $1.33
    downward going graph

    1.13%

    Downside

    Day's Volatility :6.0%

    Upside

    4.93%

    downward going graph
  • $0.59
    $10.77
    $1.33
    downward going graph

    55.62%

    Downside

    52 Weeks Volatility :94.52%

    Upside

    87.65%

    downward going graph

Returns

PeriodAclaris Therapeutics IncSector (Health Care)Index (Russel 2000)
3 Months
8.2%
6.0%
0.0%
6 Months
4.76%
5.6%
0.0%
1 Year
-86.6%
8.5%
0.0%
3 Years
-91.54%
13.8%
-19.6%

Highlights

Market Capitalization
94.8M
Book Value
$1.99
Earnings Per Share (EPS)
-1.09
PEG Ratio
-0.13
Wall Street Target Price
1.84
Profit Margin
-248.28%
Operating Margin TTM
-672.69%
Return On Assets TTM
-31.9%
Return On Equity TTM
-48.47%
Revenue TTM
31.1M
Revenue Per Share TTM
0.44
Quarterly Revenue Growth YOY
-5.1%
Gross Profit TTM
-60.0M
EBITDA
-117.6M
Diluted Eps TTM
-1.09
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.8
EPS Estimate Next Year
-0.63
EPS Estimate Current Quarter
-0.29
EPS Estimate Next Quarter
-0.25

Analyst Recommendation

Hold
    40%Buy
    60%Hold
    0
    0%Sell
Based on 15 Wall street analysts offering stock ratings for Aclaris Therapeutics Inc(by analysts ranked 0 to 5 stars)
Based on 15 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
6
6
6
Hold
9
9
9
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 38.35%

Current $1.33
Target $1.84

Company Financials

FY18Y/Y Change
Revenue
10.1M
↑ 499.58%
Net Income
-132.7M
↑ 93.71%
Net Profit Margin
-1.3K%
↑ 2756.07%
FY19Y/Y Change
Revenue
4.2M
↓ 58.11%
Net Income
-142.9M
↑ 7.62%
Net Profit Margin
-3.4K%
↓ 2064.06%
FY20Y/Y Change
Revenue
6.5M
↑ 53.35%
Net Income
-51.2M
↓ 64.19%
Net Profit Margin
-789.17%
↑ 2590.3%
FY21Y/Y Change
Revenue
6.8M
↑ 4.3%
Net Income
-114.3M
↑ 123.41%
Net Profit Margin
-1.7K%
↓ 901.13%
FY22Y/Y Change
Revenue
29.8M
↑ 340.05%
Net Income
-88.7M
↓ 22.42%
Net Profit Margin
-298.0%
↑ 1392.3%
FY23Y/Y Change
Revenue
31.2M
↑ 5.03%
Net Income
-88.5M
↓ 0.2%
Net Profit Margin
-283.15%
↑ 14.85%
Q4 FY22Q/Q Change
Revenue
7.8M
↓ 59.23%
Net Income
-33.3M
↑ 56.81%
Net Profit Margin
-429.4%
↓ 317.77%
Q1 FY23Q/Q Change
Revenue
2.5M
↓ 67.39%
Net Income
-26.4M
↓ 20.69%
Net Profit Margin
-1.0K%
↓ 614.98%
Q2 FY23Q/Q Change
Revenue
1.9M
↓ 26.07%
Net Income
-29.6M
↑ 12.0%
Net Profit Margin
-1.6K%
↓ 537.7%
Q3 FY23Q/Q Change
Revenue
9.3M
↑ 396.63%
Net Income
-29.3M
↓ 1.04%
Net Profit Margin
-315.24%
↑ 1266.84%
Q4 FY23Q/Q Change
Revenue
17.6M
↑ 89.29%
Net Income
-1.5M
↓ 94.9%
Net Profit Margin
-8.49%
↑ 306.75%
Q1 FY24Q/Q Change
Revenue
2.4M
↓ 86.35%
Net Income
-16.9M
↑ 1036.22%
Net Profit Margin
-706.46%
↓ 697.97%
FY18Y/Y Change
Total Assets
275.6M
↑ 13.16%
Total Liabilities
60.4M
↑ 231.24%
FY19Y/Y Change
Total Assets
98.3M
↓ 64.33%
Total Liabilities
28.4M
↓ 53.04%
FY20Y/Y Change
Total Assets
70.8M
↓ 27.99%
Total Liabilities
33.1M
↑ 16.73%
FY21Y/Y Change
Total Assets
251.2M
↑ 254.9%
Total Liabilities
53.9M
↑ 62.58%
FY22Y/Y Change
Total Assets
254.6M
↑ 1.35%
Total Liabilities
57.0M
↑ 5.76%
FY23Y/Y Change
Total Assets
197.4M
↓ 22.46%
Total Liabilities
40.2M
↓ 29.4%
Q4 FY22Q/Q Change
Total Assets
254.6M
↓ 4.87%
Total Liabilities
57.0M
↑ 19.21%
Q1 FY23Q/Q Change
Total Assets
229.7M
↓ 9.78%
Total Liabilities
52.9M
↓ 7.16%
Q2 FY23Q/Q Change
Total Assets
235.6M
↑ 2.59%
Total Liabilities
55.9M
↑ 5.68%
Q3 FY23Q/Q Change
Total Assets
218.4M
↓ 7.34%
Total Liabilities
62.0M
↑ 10.95%
Q4 FY23Q/Q Change
Total Assets
197.4M
↓ 9.59%
Total Liabilities
40.2M
↓ 35.14%
Q1 FY24Q/Q Change
Total Assets
174.1M
↓ 11.82%
Total Liabilities
32.1M
↓ 20.32%
FY18Y/Y Change
Operating Cash Flow
-100.8M
↑ 84.42%
Investing Cash Flow
9.4M
↓ 116.82%
Financing Cash Flow
128.3M
↑ 27.77%
FY19Y/Y Change
Operating Cash Flow
-96.4M
↓ 4.33%
Investing Cash Flow
105.7M
↑ 1028.21%
Financing Cash Flow
-30.3M
↓ 123.64%
FY20Y/Y Change
Operating Cash Flow
-38.6M
↓ 59.94%
Investing Cash Flow
6.4M
↓ 93.96%
Financing Cash Flow
18.4M
↓ 160.6%
FY21Y/Y Change
Operating Cash Flow
-52.1M
↑ 34.95%
Investing Cash Flow
-167.6M
↓ 2724.58%
Financing Cash Flow
225.1M
↑ 1124.97%
FY22Y/Y Change
Operating Cash Flow
-67.6M
↑ 29.6%
Investing Cash Flow
12.6M
↓ 107.53%
Financing Cash Flow
72.9M
↓ 67.62%
Q4 FY22Q/Q Change
Operating Cash Flow
-19.1M
↑ 144.53%
Investing Cash Flow
2.7M
↑ 122.02%
Financing Cash Flow
37.0K
↓ 436.36%
Q1 FY23Q/Q Change
Operating Cash Flow
-26.4M
↑ 37.87%
Investing Cash Flow
25.8M
↑ 854.77%
Financing Cash Flow
26.7M
↑ 72181.08%
Q2 FY23Q/Q Change
Operating Cash Flow
-20.7M
↓ 21.63%
Investing Cash Flow
-19.7M
↓ 176.22%
Financing Cash Flow
26.7M
↑ 0.0%
Q3 FY23Q/Q Change
Operating Cash Flow
-24.6M
↑ 18.9%
Investing Cash Flow
32.5M
↓ 265.47%
Financing Cash Flow
-87.0K
↓ 100.33%

Technicals Summary

Sell

Neutral

Buy

Aclaris Therapeutics Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Aclaris Therapeutics Inc
Aclaris Therapeutics Inc
2.33%
4.76%
-86.6%
-91.54%
-33.33%
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
-4.74%
-11.9%
-15.49%
-31.45%
63.1%
Agilent Technologies Inc.
Agilent Technologies Inc.
-2.44%
-0.58%
3.18%
-12.32%
90.74%
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
-5.58%
-3.44%
-6.5%
1.88%
83.17%
Danaher Corp.
Danaher Corp.
-5.15%
4.99%
-5.6%
-15.72%
71.97%
Iqvia Holdings Inc.
Iqvia Holdings Inc.
4.9%
3.13%
-1.57%
-8.31%
43.71%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Aclaris Therapeutics Inc
Aclaris Therapeutics Inc
NA
NA
-0.13
-0.8
-0.48
-0.32
NA
1.99
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
45.66
45.66
4.75
11.06
0.72
0.23
NA
18.93
Agilent Technologies Inc.
Agilent Technologies Inc.
31.64
31.64
2.7
5.21
0.21
0.08
0.01
21.31
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
34.72
34.72
2.81
21.7
0.14
0.05
0.0
119.24
Danaher Corp.
Danaher Corp.
44.83
44.83
3.13
6.95
0.08
0.04
0.0
72.16
Iqvia Holdings Inc.
Iqvia Holdings Inc.
30.68
30.68
1.33
11.08
0.22
0.05
NA
34.82
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Aclaris Therapeutics Inc
Aclaris Therapeutics Inc
Hold
$94.8M
-33.33%
NA
-248.28%
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
Buy
$38.9B
63.1%
45.66
23.26%
Agilent Technologies Inc.
Agilent Technologies Inc.
Buy
$39.7B
90.74%
31.64
18.84%
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
Buy
$206.4B
83.17%
34.72
14.2%
Danaher Corp.
Danaher Corp.
Buy
$181.3B
71.97%
44.83
18.55%
Iqvia Holdings Inc.
Iqvia Holdings Inc.
Buy
$41.0B
43.71%
30.68
9.01%

Insights on Aclaris Therapeutics Inc

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 17.57M → 2.39M (in $), with an average decrease of 86.4% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -1.49M → -16.94M (in $), with an average decrease of 1036.2% per quarter

  • Vs A

    In the last 1 year, Agilent Technologies Inc. has given 3.3% return, outperforming this stock by 90.9%

  • Vs TMO

    In the last 3 years, Aclaris Therapeutics Inc has experienced a drawdown of -91.5%, however Thermo Fisher Scientific, Inc. resisted the overall trend and outperformed by 79.2%

Institutional Holdings

  • BML Capital Management LLC

    13.18%
  • BlackRock Inc

    7.30%
  • Vanguard Group Inc

    6.92%
  • D. E. Shaw & Co LP

    4.61%
  • Millennium Management LLC

    4.59%
  • Bain Capital Life Sciences Investors, LLC

    4.21%

Company Information

aclaris therapeutics, inc. is a dermatologist-led biopharmaceutical company committed to identifying, developing and commercializing innovative therapies to address significant unmet needs in dermatology, both medical and aesthetic, and immunology. aclaris is focused on market segments with no fda-approved medications or where treatment gaps exist. aclaris was founded by dermatologists and is led by a team with extensive experience in developing and commercializing dermatologic treatments.

Organization
Aclaris Therapeutics Inc
Employees
86
CEO
Dr. Neal S. Walker D.O., M.D.
Industry
Health Technology

FAQs